Transgene Biotek Balance Sheet Health
Financial Health criteria checks 2/6
Transgene Biotek has a total shareholder equity of ₹108.3M and total debt of ₹139.6M, which brings its debt-to-equity ratio to 128.9%. Its total assets and total liabilities are ₹1.4B and ₹1.3B respectively.
Key information
128.9%
Debt to equity ratio
₹139.59m
Debt
| Interest coverage ratio | n/a |
| Cash | ₹113.00k |
| Equity | ₹108.32m |
| Total liabilities | ₹1.31b |
| Total assets | ₹1.42b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 526139's short term assets (₹8.9M) do not cover its short term liabilities (₹109.6M).
Long Term Liabilities: 526139's short term assets (₹8.9M) do not cover its long term liabilities (₹1.2B).
Debt to Equity History and Analysis
Debt Level: 526139's net debt to equity ratio (128.8%) is considered high.
Reducing Debt: 526139's debt to equity ratio has increased from 25.6% to 128.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 526139 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 526139 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 74.8% per year.